Starlab Space Announces LambdaVision as Latest Customer for its On-Orbit Science Park
MWN-AI** Summary
Starlab Space LLC, a developer of commercial space stations, has partnered with LambdaVision, a biotechnology company focused on creating protein-based artificial retinas, to advance space-based commercial manufacturing. Through a reservation agreement, LambdaVision will transition its research activities to Starlab’s facilities, which are designed to allow for scalable biomanufacturing in low Earth orbit as the International Space Station nears the end of its operational life.
The agreement is pivotal for LambdaVision as it seeks to leverage the unique microgravity environment to enhance the quality and functionality of its retinal implants. LambdaVision's layer-by-layer assembly process benefits from microgravity, which improves the homogeneity and stability of the protein-based films needed for their artificial retinas. This innovative approach positions the company to not only restore vision for individuals suffering from retinal degenerative diseases like retinitis pigmentosa and age-related macular degeneration but also to explore broader applications in fields such as biosensors, drug delivery, and tissue engineering.
LambdaVision’s CEO, Dr. Nicole Wagner, emphasized that the collaboration with Starlab allows for sustainable manufacturing in microgravity, demonstrating the feasibility of producing therapeutic technologies at scale. According to Dr. Luis Zea, Starlab's chief scientist, this partnership is a significant step in commercializing in-space manufacturing processes while delivering crucial benefits to patients on Earth.
Starlab’s model offers researchers a cost-effective and efficient pathway to access low Earth orbit, facilitating a seamless transition from the International Space Station to its advanced facilities. With strategic partners including major corporations and universities, Starlab aims to ensure continued human presence and scientific inquiry in space.
MWN-AI** Analysis
The recent announcement of Starlab Space LLC entering into a reservation agreement with LambdaVision marks a significant milestone in the commercial space sector, particularly for biotechnology and medical research. This collaboration aims to facilitate LambdaVision’s pursuit of space-based manufacturing for its innovative protein-based artificial retina. Analysts suggest investors should view this as a critical juncture, given that the International Space Station (ISS) is nearing retirement, which further underscores the necessity and urgency for such advancements in low Earth orbit (LEO).
Investors interested in the aerospace and biotechnology sectors should consider the potential synergies presented by this partnership. Starlab’s capabilities in biopharmaceutical research, combined with LambdaVision’s pioneering approach to protein manufacturing, open numerous avenues for growth. The enhancement of LambdaVision’s layer-by-layer assembly process underscores the competitive advantage of utilizing microgravity for biopharmaceutical applications—where consistency and uniformity are paramount.
Moreover, the agreement positions LambdaVision to leverage Starlab’s infrastructure as it scales its production capabilities. This is particularly promising not just for restoring vision in patients suffering from retinal degenerative diseases, but it also paves the way for broader applications in precision biological manufacturing—impacting sectors like drug delivery and tissue engineering.
Investors might also consider Starlab’s robust business model, designed to lower operational risks and streamline research transitions, making it a compelling investment opportunity in the evolving landscape of private space exploration. As the market for commercial space research accelerates, companies like Starlab and LambdaVision are likely to play pivotal roles in shaping the future of biotechnology and medical innovation, addressing global health challenges.
In conclusion, stakeholders in these sectors should closely monitor developments from this partnership, as it may signal transformational shifts and investment opportunities within the bio-manufacturing and space research industries.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LambdaVision will extend its research and production activities to Starlab as they advance toward space-based commercial manufacturing of protein-based artificial retinas.
Starlab Space LLC , the commercial space station developer expanding access to low Earth orbit research, today announced a reservation agreement with LambdaVision , a biotechnology company developing a protein-based artificial retina designed to restore vision for patients with retinal degenerative diseases. The reservation agreement supports LambdaVision’s transition from research to long-term, scalable biomedical production in space and ensures its continued access to microgravity as the International Space Station approaches retirement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224814115/en/
Space Tango and LambdaVision CubeLabs on the International Space Station, containing optimized and automated hardware for layer-by-layer deposition development of LambdaVision’s artificial retina in microgravity. LambdaVision will extend its research and production activities to Starlab as they advance toward space-based commercial manufacturing of protein-based artificial retinas.
LambdaVision’s layer-by-layer assembly process is improved in the low Earth orbit environment, where reduced gravity improves homogeneity, stability and performance of thin films like the protein-based artificial retina. The company has successfully validated its microgravity manufacturing method and plans to improve the quality and functionality of its protein-based artificial retina, while paving the way for novel innovations in other fields.
“Our agreement with Starlab is a critical step in ensuring continued access to low Earth orbit as we advance toward commercial manufacturing,” said Nicole Wagner, Ph.D., CEO of LambdaVision. “We are positioning our protein-based artificial retina and our layer-by-layer technology more broadly for long-term growth beyond the ISS. This approach not only supports our mission to help restore vision on Earth but also opens the door to new research and commercial opportunities by demonstrating that therapies can be produced in low Earth orbit at a commercial scale.”
While LambdaVision’s first application is restoring vision, its layer-by-layer protein manufacturing platform has broader potential. By producing highly uniform, stable protein films in microgravity, the company is advancing a new approach to precision biological manufacturing that could enable improved materials for sensitive biosensors, optical systems, drug delivery applications and tissue engineering.
“LambdaVision has demonstrated the maturity of the science, engineering, and in-space manufacturing processes required to produce retinal implants in microgravity,” said Luis Zea, Ph.D., chief scientist at Starlab. “Their reservation with Starlab enables the transition from demonstration to scalable, sustainable manufacturing, unlocking exponential growth while delivering meaningful benefits to patients on Earth. We are proud to work with LambdaVision to harness the unique advantages of microgravity to do good in the world.”
The announcement builds on Starlab’s growing capabilities in biopharmaceutical and life sciences research in orbit. Microgravity offers conditions that cannot be replicated on Earth, allowing for reduced sedimentation and improved material uniformity, which support higher consistency in protein-based structures and directly impact therapeutic quality, reproducibility and regulatory readiness.
Starlab’s market-driven business model is designed to reduce cost, complexity and risk for researchers and commercial partners. Its single-launch, no-assembly-required architecture enables full certification and operational readiness within weeks from launch, minimizing delays and maximizing efficiency for payload customers. Through its joint venture partners, customers can conduct research aboard the International Space Station today, ensuring a seamless transition to Starlab as its next-generation capabilities come online.
About Starlab
Starlab Space is a U.S.-led, global joint venture among Voyager Technologies (NYSE: VOYG), Airbus , Mitsubishi Corporation , MDA Space , Palantir Technologies , and Space Applications Services , with strategic partners including Hilton, Journey, Northrop Grumman, and The Ohio State University. Starlab is developing a next-generation, AI-enabled commercial space station, aiming to ensure continued human presence in low-Earth orbit and a seamless transition of microgravity science and research alongside the retirement of the International Space Station. Starlab's advanced, user-driven design and robust capabilities make it a premier platform for scientific discovery and technological advancement in space. For more information, visit starlab-space.com .
About LambdaVision
LambdaVision is leveraging space to develop a protein-based artificial retina to restore meaningful vision for the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The patent-protected artificial retina technology developed by LambdaVision uses photoactive proteins to naturally mimic the light-absorbing properties of human photoreceptor cells and activate neuroreceptors still present in degenerated retinas of blind patients. LambdaVision’s artificial retina is one of the first technologies being evaluated on the International Space Station that has potential for clinical use, and the established microgravity manufacturing processes, quality control methods, and laboratory techniques provide a foundation for future clinical research in space. To learn more, visit lambdavision.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260224814115/en/
MEDIA CONTACT:
Starlab Space
Melissa Price, melissaprice@griffincg.com
LambdaVision
Kristin Rose Jutras, Kristin.jutras@tmstrat.com
FAQ**
How does the partnership between LambdaVision and Starlab, particularly with Voyager Technologies Inc. Class A VOYG, enhance the scalability of protein-based artificial retina production in microgravity?
What are the anticipated commercial and research opportunities that may arise from LambdaVision's production of artificial retinas aboard Starlab, in collaboration with Voyager Technologies Inc. Class A VOYG?
In what ways does the layer-by-layer assembly process utilized by LambdaVision benefit from the microgravity environment provided by Starlab and Voyager Technologies Inc. Class A VOYG?
How might the advancements in protein-based manufacturing and retinal restoration technologies supported by Starlab and Voyager Technologies Inc. Class A VOYG influence future applications in other biomedical fields?
**MWN-AI FAQ is based on asking OpenAI questions about Voyager Technologies Inc. Class A (NYSE: VOYG).
NASDAQ: VOYG
VOYG Trading
6.34% G/L:
$36.21 Last:
1,371,870 Volume:
$36.20 Open:
